Introduction
============

Esophageal cancer is the 8th most common cancer and 6th leading cause of cancer mortality in the word [@B1], [@B2]. The major pathological types of this cancer are adenocarcinomas in Europe and United States [@B3], and squamous cell carcinoma in Asia [@B2]. Three-field lymph node dissection is now considered as a standard procedure in the treatment of thoracic esophageal carcinoma, however, the use of surgery alone still results in high rates of locoregional recurrence and distant metastasis [@B4], [@B5]. It has been reported that the presence of lymph node metastasis and the number of involved nodes are important prognostic factors for survival after surgery [@B6]-[@B8]. Patients with local regional lymph node metastasis had worse prognosis than those without [@B8]-[@B10]. Even after radical surgery, the 5-year overall survival (OS) of patients with lymph node positive esophageal squamous cell carcinoma (ESCC) was only 14.7-38% [@B8]-[@B10]. Therefore, combined-modality therapy that included adjuvant chemotherapy and radiotherapy were used to reduce the rate of recurrence and to improve the survival outcome after surgery.

The reported efficacy of postoperative adjuvant radiotherapy in the treatment of thoracic ESCC was conflicting [@B11]-[@B13]. Only a few retrospective studies with small sample size comparing postoperative chemoradiotherapy (CRT) with surgery alone had been reported in the literature [@B14], [@B15]. Whether adjuvant CRT can improve the survival of patients with esophageal carcinoma is still under debate. In fact, there is no generally accepted strategy for postoperative treatment of ESCC patients in China, and the treatment regimens are mainly based on tumor stage, the doctors\' and/or patients\' preferences. The purpose of this study is to explore optimal postoperative therapeutic modalities in the treatment of ESCC by retrospectively reviewing the outcomes of adjuvant treatment in ESCC patients at our institute from 2010 to 2015.

Materials and Methods
=====================

Patients
--------

The eligibility criteria for this study were as follows: patients had undergone radical esophagectomy with 3-field lymph node dissection and were pathologically confirmed with stage II ⁄ III thoracic ESCC; Liver and kidney function and results of blood tests were normal. Heart and lung function were not obviously damaged, and patients were supposed to be able to tolerate chemotherapy; Eastern Cooperative Oncology Group performance status \<2. The exclusion criteria were as follows: patients with preoperative chemotherapy or preoperative radiotherapy; with a type of esophageal cancer other than squamous cell carcinoma (SCC) or with cancer at other site; with a history of cancer at any other site; and those lost to follow-up.

According to the type of postoperative adjuvant treatments, patients were classified into three groups: surgery alone (Group S), adjuvant chemotherapy alone (Group CT) and postoperative concurrent chemoradiotherapy (Group CRT). This study was approved by the Institutional Review Board and performed at the 1st Affiliated Hospital of Wenzhou Medical University. The informed consents from all the patients were obtained.

Surgical procedure
------------------

All patients included in our study underwent curative resection by total or subtotal thoracic esophagectomy and 3-field lymph node dissection, which included the subcarinal, paraesophageal, pulmonary ligament, diaphragmatic, paracardial, and left gastric artery lymph nodes. Esophageal reconstruction was performed using stomach, colon, or jejunum. Pathological staging and tumor location were uniformly defined according to the 7th edition of American Joint Committee on Cancer (AJCC) Guidelines [@B16]. Regional lymph nodes (N) extend from periesophageal cervical nodes to celiac nodes. N1, N2, and N3 indicated metastasis in 1 to 2, 3-6, and in ≥7 regional lymph nodes, respectively.

Chemotherapy
------------

The first cycle of adjuvant chemotherapy was started at the 3rd to 4th week after operation. The chemotherapy regimen mainly consisted of intravenous infusion of cisplatin (75 mg/m^2^) averaged on days 1-3 plus paclitaxel (135 mg/ m^2^) on day 1 for a 21-day cycle. Another alternative chemotherapy regimen was comprised of 5-fluorouracil (5-FU) and cisplatin. Paclitaxel would also be replaced by 5-FU if patients were allergic. Cisplatin could be changed into nedaplatin. Supportive care and symptomatic treatment were provided during chemotherapy.

Chemoradiation therapy
----------------------

Radiation was given by conformal fields with T-shaped target volume that included the bilateral supraclavicular area, mediastinum, and subcarinal area for lesions in the upper thoracic segment of the esophagus. The superior boundary of the middle thoracic segment was the upper edge of the first thoracic vertebra. The upper border of the lower thoracic segment was 3 cm above the upper edge of the gross tumor based on preoperative computed tomography (CT) images. The inferior border of the midlower thoracic segment was 3-4 cm below the lower edge of the gross tumor, as identified on preoperative CT images. The field contained the related drainage areas of the lymph nodes in the mediastinum and the primary esophageal tumor bed. A total dose of 50 Gy was delivered at 2.0 Gy per fraction over a 5-week period. Radiotherapy was given at a 6 MV X-Ray linear accelerator. Radiation was started day 1st when the patient in Group CRT received the first cycle of concurrent chemotherapy the same as described above.

Follow-up
---------

Follow-up was performed every 3 months for the first two years, then every 6 months for the next 3 years, annually thereafter. Follow-up examinations consisted of physical examination, a complete blood count measurement, liver function test, chest CT scan, esophagogram, and abdominal CT scan or ultrasound. Positron emission tomography, endoscopy, bone scintigraphy, and/or cerebral CT were performed if clinically indicated. Any histologic evidence, unequivocal radiologic (computed tomography, magnetic resonance imaging, and bone scintigraphy) suspicious lesions of tumor was regarded as recurrent disease. Toxicities were graded according to National Cancer Institute common terminology criteria for adverse events (CTCAE version 3.0).

Statistical analysis
--------------------

Disease-free survival (DFS) was calculated from the date of surgery to the time of first local or distant recurrence, or death from any cause. Overall survival (OS) was measured from the date of surgery to death or the last follow-up visit. Survival curves were estimated using Kaplan-Meier method and comparisons were made using the log-rank test. Categorical variables were compared using the chi-square test. Cox regression was used to estimate hazard ratios (HRs). For multivariate analysis of prognostic factors, separate Cox proportional hazards regression models were utilized to estimate the relationship between each variables and OS or DFS. A probability (p) value of \< 0.05 was considered statistically significant. All statistical analyses were performed using IBM SPSS version 22.0 (IBM, Armonk, NY, U.S.A.).

Results
=======

Clinical characteristics of the study population
------------------------------------------------

Table [1](#T1){ref-type="table"} lists the characteristics of available patients and comparisons among different treatment modalities. There were total of 408 patients met the selection criteria in our study: 191(46.8%) received surgery alone, 83 (20.3%) received postoperative chemotherapy and 134 (32.9%) received postoperative concurrent CRT, respectively. Patients in Group CRT were younger than those in the other two groups (p=0.001). The rest of the characteristics did not differ significantly among three groups (P\>0.05).

Treatment compliance
--------------------

There were 191 (88.0%) patients in Group CT and CRT together received chemotherapy consisted of paclitaxel and platinum (cisplatin or nedaplatin) every 21 days, and 12% received combinations of 5-fu and cisplatin every 21 days. Cisplatin was used in 83.4% of platinum-based chemotherapy. The median number of chemotherapy cycles were 4 (range, 2-6 cycles) and 3 (range, 2-4 cycles) in Group CT and CRT, respectively. There were five patients (6%) in Group CT excluded from the treatment protocol after two cycles of planned chemotherapy due to toxicities (3 patients) and patients\' refusal (2 patients). In Group CRT, twelve patients (9%) discontinued treatments as a result of poor tolerance (10 patients) and infection (2 patients). Only one patient dropped out of the radiotherapy protocol due to severe radiation reaction.

Survival
--------

The follow-up duration was similar for different groups with a median follow-up for all patients was 48.3 months. Overall survival rates for the entire population were 87% at 1 year, 49.8% at 3 years, and 29.3% at 5 years, respectively, with a median OS of 36 months. As shown in figure [1](#F1){ref-type="fig"}A, there was no significant difference on OS among groups (p=0.16) with 1-year, 3-year and 5-year OS of 85.3%, 85.5%, 90.2%; 44.9%, 53.9%, 54.3%; and 23.8%, 27.3%, 33.6% for Group S, CT, and CRT, respectively. The median 1- and 3-year DFS for all the patients were 75.2% and 40.3%, respectively. There was also no significant difference on DFS among groups (p=0.25) as shown in figure [1](#F1){ref-type="fig"}B with an overall 1- and 3- year DFS of 71.7% ,78.3% ,78.3%, and 35.7%, 42.4%,41.2% for Group S, CT and CRT, respectively.

For patients with positive nodal involvement, both postoperative chemotherapy and CRT provided a significant survival advantage compared with surgery alone (p=0.019; p=0.003, respectively; Fig [1](#F1){ref-type="fig"}C&D). The 3-year OS was 30.8%, 53.7%, and 50.5% for Group S, CT, and CRT, respectively. The survival rates of Group S were significantly lower than those of Group CT (p=0.04) and Group CRT (p=0.01), but no significant difference was found between Group CT and CRT (p=0.69). Similarly, the 3-year DFS were 19.9%, 41.6%, and 34.0% for Group S, CT, and CRT, respectively. The DFS of Group S were significantly lower than those of Group CT (p=0.01) and Group CRT (p=0.003), but no significant difference was found between Group CT and CRT (p=0.64).

On stratification according to the number of lymph nodes, subgroup analyses of patients with metastasis of N1 (1 or 2 locoregional lymph nodes) showed no survival difference among the three groups (p=0.082; p=0.065, respectively; Fig [2](#F2){ref-type="fig"}A&B). However, for patients with metastasis of N2 + N3 (3 or more locoregional lymph nodes), patients of Group S had significantly worse OS and DFS than those in the other two groups (p=0.04; p=0.004, respectively; Fig [2](#F2){ref-type="fig"}C&D). The 3-year OS were 22.0%, 44.9%, and 35.2% for Group S, CT, and CRT, respectively. The 3-year DFS was 11.8%, 30.8%, and 17.7% for Group S, CT, and CRT, respectively. OS and DFS were not significantly different between Group CT and Group CRT (p=0.42; p=0.49, respectively; Fig [2](#F2){ref-type="fig"}C&D).

To explore the influence of tumor location on survival, the effects of adjuvant treatments on patients with tumors in the middle and lower thoracic segments (the number of patients who had tumors in the upper thoracic segments was too small to do subgroup analyses) were compared. For patients who had tumors in the middle thoracic region, the 3-year OS were 43.9%, 61.0%, and 63.4% for Group S, CT, and CRT, respectively. The survival rates of Group S were significantly lower than those of Group CT (P=0.03) and Group CRT (P=0.007), but no significant difference was found between Group CT and CRT (P=0.59; Fig [3](#F3){ref-type="fig"}A). Likewise, the 3-year DFS were 32.4%, 45.7%, and 45.8% for Group S, CT, and CRT, respectively. The DFS of Group S were significantly lower than those of Group CT (P=0.04) and Group CRT (P=0.006), but no significant difference was found between Group CT and CRT (P=0.23; Fig [3](#F3){ref-type="fig"}B). For patients who had tumors in the lower thoracic region, OS and DFS were not significantly different among groups (p=0.386; p=0.089, respectively; Fig [3](#F3){ref-type="fig"}C&D).

Failure analysis of patients with positive lymph nodes
------------------------------------------------------

The failure patterns of patients with positive lymph nodes were detailed in Table [2](#T2){ref-type="table"}. Local recurrence rates were similar among the three groups (p=0.10). However, Group CRT had significantly fewer cases of hematogenous metastasis and overall recurrence (P=0.04; p=0.01, respectively).

Univariate and multivariate analyses of prognostic factors
----------------------------------------------------------

Univariate analysis showed that OS and DFS were significantly associated with sex, tumor differentiation, number of positive lymph nodes, extent of resection and AJCC stage, but they were not significantly associated with age at diagnosis, tumor location, and depth of invasion (Table [3](#T3){ref-type="table"}). Multivariate analysis showed that number of positive lymph nodes, extent of resection and AJCC stage were independent prognostic factors (Table [4](#T4){ref-type="table"}).

Toxicities of postoperative chemotherapy and chemoradiotherapy
--------------------------------------------------------------

No significant difference in the incidences of gastrointestinal disorder and Grade 3-4 myelosuppression was found between the 2 groups (p\>0.05). Grade 1-2 myelosuppression was experienced significantly more frequently by patients in Group CRT than those in Group CT (P=0.03) (Table [5](#T5){ref-type="table"}). Late toxicities were rare and manageable overall.

Discussion
==========

High rates of local-regional and distant recurrence resulted in the death of resected esophageal cancer patients have leaded to intense exploration on the application of multidisciplinary approaches in the treatment of esophageal cancer. National Comprehensive Cancer Network (NCCN) guidelines recommend preoperative neoadjuvant CRT for patients with locally advanced esophageal cancer. However, no additional postoperative adjuvant treatment was recommended unless for postive margins. Yet, even patients underwent extensive operation with unfavourable prognosis. Most existing literatures on adjuvant treatments were hindered by their retrospective nature or small numbers of ESCC included. Therefore, no clear consensuses in the treatment of postoperative ESCC had been reached.

In this study, the retrospective outcomes of adjuvant treatments suggested that paclitaxel-based adjuvant chemotherapy and CRT both significantly increased OS and DFS compared to surgery alone in lymph node positive ESCC patients, particularly in patients with three or more lymph nodes involvement and with tumors in the middle thoracic region. Postoperative CRT decreased the rates of distant metastasis and overall recurrence for patients with positive lymph nodes. Furthermore, this study showed that no significant difference in survival was found between postoperative CT and CRT Groups.

Only a few studies are available on the efficacy of postoperative chemotherapy. Ando et al conducted a randomized controlled trial and compared postoperative adjuvant chemotherapy with surgery alone. Their report demonstrated that adjuvant chemotherapy with cisplatin and fluorouracil improved 5-year DFS in patients with ESCC, especially in subgroup patients with lymph node metastasis. However, no significant difference was found in 5-year OS between two groups [@B9]. Similarly, a non-randomized prospective study conducted by Lee et al suggested that postoperative chemotherapy might prolong DFS in lymph node-positive, curatively resected esophageal cancer patients. This study failed to demonstrate OS benefit in the adjuvant group either [@B17]. Recently, Lyu et al retrospectively reviewed 349 ESCC patients with positive lymph node metastasis and showed that postoperative adjuvant chemotherapy with more than four cycles of taxane-based regimens prolonged overall survival [@B18]. Meanwhile, a meta-analysis indicated ESCC patients with stage III-IV diseases could benefit from adjuvant chemotherapy on 3-year OS [@B19]. Our study suggested that paclitaxel-based adjuvant chemotherapy increased OS and DFS compared to surgery alone in lymph node positive ESCC patients. These together showed that postoperative adjuvant chemotherapy might improve survival for certain small fraction of ESCC patients according to their pathological stages or their status of lymph node metastasis.

With regard to postoperative CRT, there also have been limited numbers of literatures exploring its use in ESCC patients. A prospectively, non-randomly trial conducted by Hung-Chang Liu et al showed that postoperative concurrent chemoradiotherapy (CCRT) with weekly cisplatin significantly increased OS for patients with locally advanced esophageal cancer compared with radiotherapy alone (30.9 mo vs 20.7 mo; 95% CI, 27.5-36.4 vs 15.2-26.1) [@B20]. Po-Kuei Hsu et al retrospectively reviewed 290 ESCC patients and found that postoperative CRT provided a survival benefit for patients with positive lymph node involvement (CRT versus S group: median OS 29.0 versus 16.0 months, 3-year OS rate 48.6% versus 16.8%; p=0.003) [@B21]. Junqiang Chen and coworkers also reported a significant survival advantage with postoperative CRT in node-positive ESCC patients compared with radiotherapy alone (p=0.03) [@B22]. In addition to survival benefits, the study of Junqiang Chen and our study both demonstrated lower frequency of distant and overall recurrence in Group CRT compared with Group S, indicating that surgery plus chemoradiation is more efficient for distant control than surgery alone.

The current study also found that postoperative CT and CRT both were associated with improved survival rates for patients with tumors in the middle thoracic regions but not for those with tumor in the lower region. Similarly, a previous study suggested postoperative radiotherapy was particularly beneficial for patients with positive lymph nodes in the upper (supraclavicular and upper mediastinal) region or both the upper and lower (mediastinal and abdominal) regions but not for those with only lower-region node disease. (p \< 0.05) [@B12]. This study also demonstrated a better survival rate for patients with metastases in the lower region than those with metastases in the upper region or both the upper and lower regions (p \< 0.0001). One possible explanation is that the middle and lower mediastinum and upper abdominal areas could be well exposed to achieve a relatively more thorough lymph node dissection. On the other hand, lymph node dissection in the lower neck and upper mediastinal regions is difficult due to the complex anatomy in those regions. Thus, postoperative chemotherapy and radiotherapy can reduce the recurrence rate of subclinical lesions which might be left behind by incomplete dissection and can reduce the incidence of latent distant metastasis. This was in line with our results, in which patients in Group S had the largest number of distant and overall recurrences.

Our study showed there was no notable difference in OS and DFS between the adjuvant CT and CRT Groups. Similarly, a previous prospective randomized clinical trial conducted by Tachibana et al reported that postoperative radiotherapy administered concurrently with cisplatin and 5-fluorouracil chemotherapy did not provide a survival benefit compared with chemotherapy alone [@B23]. To our knowledge, there were no other randomized reports exploring the effects and toxicities of postoperative CRT compared with chemotherapy alone since then. In this study, mild myelosuppression was significantly more common in the Group CRT than in the Group CT. No significant difference in the incidence of gastrointestinal disorder and severe myelosuppression was found between the 2 groups. Similarly, many studies showed that the incidence of complications was high in the CRT group and most complications due to CRT were chemotherapy-related [@B22], [@B24], [@B25]. However, paclitaxel-based adjuvant chemotherapy was in general well tolerated and no treatment-related death was observed in our study. Most of the complications were manageable and could be reversed by supportive care.

Multivariate analysis in the present study showed that the number of metastatic lymph nodes, extent of resection, and AJCC stage were independent prognostic factors for OS and DFS. These findings were consistent with the published literatures [@B26]-[@B29].

Owing to the retrospective nature of our study and the small number of patient size, it was difficult to make a definite conclusion about the best treatment of thoracic ESCC patients. Our analysis suggested that postoperative chemotherapy and CRT have similar survival rate and both may benefit ESCC patients with positive lymph nodes, especially those with metastasis of 3 or more locoregional lymph nodes and with tumors in the middle thoracic segment. Postoperative CRT was significantly more effective at reducing the rates of distant metastasis and overall recurrence for patients with positive lymph nodes. Mild myelosuppression was more common with CRT than with chemotherapy alone, but patients could tolerate CRT. Multicenter randomized trials with large sample size are needed to confirm our results. Further investigation in lymph node positive resected ESCC to compare the effects of postoperative CRT with chemotherapy alone is warranted.
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CT
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###### 

Comparison of patient characteristics by treatment assignment

  Characteristic                No. of patients (%)                                               
  ----------------------------- --------------------- ----------- ---------- ----------- -------- -------
  Sex                                                                                    2.544    0.694
  Male                          360(88.2)             169(88.5)   75(90.3)   116(86.6)            
  Female                        48(11.8)              22(11.5)    8(9.7)     18(13.4)             
  Age at diagnosis (y)                                                                   13.951   0.001
  \<60                          201(49.3)             89(46.6)    42(50.6)   90(67.2)             
  ≥60                           207(50.7)             102(53.4)   41(49.4)   44(32.8)             
  Smoking                                                                                1.943    0.379
  Yes                           253(62.0)             121(63.4)   46(55.4)   86(64.2)             
  No                            155(38.0)             70(36.6)    37(44.6)   48(35.8)             
  Tumor location                                                                         4.734    0.316
  Upper thoracic segment        34(8.3)               18(9.4)     8(9.6)     8(6.0)               
  Middle thoracic segment       242(59.3)             114(59.7)   42(50.6)   86(64.2)             
  Lower thoracic segment        132(32.4)             59(30.9)    33(39.8)   40(29.9)             
  Tumor differentiation                                                                  2.264    0.687
  Grade I                       88(21.6)              38(19.9)    22(26.5)   28(20.9)             
  Grade II                      201(49.3)             94(49.2)    37(44.6)   70(52.2)             
  Grade III                     119(29.2)             59(30.9)    24(28.9)   36(26.9)             
  Depth of invasion (%)                                                                  0.930    0.920
  T2                            118(28.9)             51(26.7)    25(30.1)   42(31.3)             
  T3                            252(61.8)             122(63.9)   50(60.2)   80(59.7)             
  T4                            38(9.3)               18(9.4)     8(9.6)     12(9.0)              
  No. of positive lymph nodes                                                            10.063   0.122
  N0                            137(33.6)             75(39.3)    22(26.5)   40(29.9)             
  N1                            167(40.9)             78(40.8)    35(42.2)   54(40.3)             
  N2                            86(21.1)              34(17.8)    20(24.1)   32(23.9)             
  N3                            18(4.4)               4(2.1)      6(7.2)     8(6.0)               
  Extent of resection (%)                                                                0.034    0.983
  R0                            370(90.7)             173(90.6)   75(90.4)   122(91.0)            
  R1                            38(9.3)               18(9.4)     8(9.6)     12(9.0)              
  7th AJCC stage                                                                         7.410    0.493
  IIA                           50(12.3)              32(16.8)    6(7.2)     12(9.0)              
  IIB                           121(29.7)             54(28.3)    25(30.1)   42(31.3)             
  IIIA                          130(31.9)             60(31.4)    28(33.7)   42(31.3)             
  IIIB                          62(15.2)              26(13.6)    14(16.9)   22(16.4)             
  IIIC                          45(11.0)              19(9.9)     10(12.0)   16(11.9)             

Abbreviations: AJCC=American Joint Committee on Cancer (2009 criteria); S=surgery alone; CT=chemotherapy alone; CRT=chemotherapy plus radiation therapy;

###### 

Failure patterns of patients with positive lymph nodes

                            No. of patients (%)                                 
  ------------------------- --------------------- ---------- ---------- ------- -------
  Local recurrence, total   42(37.1)              20(32.8)   22(23.4)   4.578   0.101
  Supraclavicular           12(10.3)              5(8.2)     4(4.3)             
  Mediastinum               21(18.1)              9(14.8)    10(10.6)           
  Abdominal cavity          7(6.0)                5(8.2)     5(5.3)             
  Tumor bed                 7(6.0)                4(6.6)     3(3.2)             
  Hematogenous metastasis   38(32.5)              13(21.3)   17(18.1)   6.33    0.042
  Mixed                     10(8.6)               2(3.3)     2(2.1)     4.49    0.101
  Overall                   70(60.3)              31(50.8)   37(39.4)   9.148   0.01

Abbreviations: AJCC=American Joint Committee on Cancer (2009 criteria); S=surgery alone; CT=chemotherapy alone; CRT=chemotherapy plus radiation therapy.

###### 

Univariate analysis of factors predictive of survival

                                DFS     OS                                  
  ----------------------------- ------- -------- --------- ------- -------- ---------
  Sex                                                                       
  Male                          24.00   5.451    0.020     35.13   5.679    0.017
  Female                        36.30                      42.00            
  Age at diagnosis (y)                                                      
  \<60                          24.30   0.218    0.640     35.27   1.180    0.277
  \>=60                         26.00                      38.17            
  Tumor location                                                            
  Upper thoracic segment        8.00    2.110    0.348     11.10   3.626    0.163
  Middle thoracic segment       26.20                      38.00            
  Lower thoracic segment        22.00                      32.33            
  Tumor differentiation                                                     
  Grade I                       24.00   15.839   \<0.001   36.00   15.297   \<0.001
  Grade II                      29.03                      41.00            
  Grade III                     19.60                      26.30            
  Depth of invasion (%)                                                     
  T2                            34.00   5.080    0.079     41.00   2.462    0.292
  T3                            23.10                      35.50            
  T4                            23.00                      32.50            
  No. of positive lymph nodes                                               
  N0                            36.7    37.780   \<0.001   47.0    23.577   \<0.001
  N1                            20.0                       36.0             
  N2                            23.0                       33.0             
  N3                            10.0                       13.0             
  Extent of resection (%)                                                   
  R0                            26.0    13.403   \<0.001   38.00   21.921   \<0.001
  R1                            15.6                       23.03            
  7th AJCC stage                                                            
  IIA                           36.90   27.125   \<0.001   61.00   21.529   \<0.001
  IIB                           36.00                      41.00            
  IIIA                          23.00                      37.00            
  IIIB                          21.90                      29.50            
  IIIC                          16.17                      25.00            

Abbreviations: DFS=disease-free survival; OS=overall survival; AJCC=American Joint Committee on Cancer (2009 criteria)

###### 

Multivariate analysis of prognostic factors for survival

                                         DFS                                    OS                   
  ------------------------------ ------- -------------------- --------- ------- -------------------- ---------
  No. of lymph node metastases           1.377(1.203,1.575)   \<0.001           1.128(1.087,1.645)   0.032
  N0                             36.7                                   47.0                         
  N1                             20.0                                   36.0                         
  N2                             23.0                                   33.0                         
  N3                             10.0                                   13.0                         
  Extent of resection                    1.692(1.187,2.413)   0.004             2.100(1.448,3.047)   \<0.001
  R0                             26.0                                   38.00                        
  R1                             15.6                                   23.03                        
  7th AJCC stage                         1.130(1.043,1.339)   0.013             1.242(1.108,1.392)   \<0.001
  IIA                            36.90                                  61.00                        
  IIB                            36.00                                  41.00                        
  IIIA                           23.00                                  37.00                        
  IIIB                           21.90                                  29.50                        
  IIIC                           16.17                                  25.00                        

Abbreviations: DFS=disease-free survival; OS=overall survival; HR = hazard ratio; CI = confidence interval. AJCC=American Joint Committee on Cancer (2009 criteria).

###### 

Toxic reactions

                              No. of patients (%)                     
  --------------------------- --------------------- ---------- ------ ------
  Gastrointestinal reaction                                           
  Grade 1-2                   15(18.1)              27(20.1)   0.14   0.71
  Grade 3-4                   2(2.4)                4(3.0)     0.06   1.0
  Myelosuppression                                                    
  Grade 1-2                   24(28.9)              58(43.2)   4.50   0.03
  Grade 3-4                   12(14.5)              33(24.6)   3.22   0.07

Abbreviations: CT=chemotherapy alone; CRT=chemotherapy plus radiation therapy.
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